AFM13-NK
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for AFM13-NK, covering 2025-09-30 to 2025-09-30. Get the full timeline:
Most recent: Clinical Trial Update: Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas [Phase 1, Phase 2]